Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Lianyungang Runzhong Pharmaceutical Co., Ltd.

Centaurus Biopharma Co., Ltd.

Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd.

Shanghai Dude Medical Science and Technology Co., Ltd.

Chia Tai Tianqing Pharmaceutical Group Go., Ltd.

Aiming Zhang

Xiquan Zhang

Chunguang Xia

Zhou Zhou

Huadong Yao

Kevin X Chen

Jian Xiong

Xin Tian

Cheng Xie

Xiongbin Xu

Lin Liu

Xingdong Cheng

Guangming Sang

Leilei Yang

Xiaopeng Guo

Wenwei Xu

Shuhui Chen

Jian Li

Xin Liu

Yu Shen

Ling Yang

Yong Peng

Yongxin Han

Hong Luo

Rui Zhao

Dengming Xiao

Gang Wu

Zhen Gong

Xueyan Zhu

Hubo Wang

Xinhe Xu

Xiaoping Chen

Rui Kong

Shan Chen

Jie Xie

Jiabin Qiao

Zhulian Jiang

Xuejin Zhang

Ce Gao

Qide Li

Lang Chen

Shufeng Wu

Xingjian Zhou

Minmin Kong

Mingming Li

The present application relates to a method for preparing trifluridine, comprising reacting a compound of formula III with a compound of formula IV in a first solvent in the presence of an acid to obtain a compound of formula II, and performing further reaction to obtain trifluridine.

Method for preparing trifluridine

A borate compound of an azetidine derivative, relating in particular to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a tautomer thereof, a stereoisomer thereof or a geometric isomer thereof, as well as a use thereof in the preparation of a drug used for the treatment or prevention of multiple myeloma. 

Borate of azetidine derivative

This application belongs to the field of pharmaceutical technology, and relates to the crystals of glycyrrhizic acid derivatives, their crystalline and pharmaceutical compositions, and medical use thereof, and, in particular, to the crystalline form A, crystalline form B, crystalline form C, crystalline form D, and crystalline form E of magnesium isoglycyrrhizinate, the method of preparing the crystals, the crystalline and pharmaceutical compositions containing the crystals, and medical use thereof. The crystalline forms prepared according to this application have overcome the defects of the compound of Formula I prepared according to the prior art, such as solid caking, difficult filtration, hard drying, and poor clarity. They are also suitable for industrial production, and capable of improving product safety.

Crystals of glycyrrhizic acid derivatives, crystalline compositions, pharmaceutical compositions and uses thereof

The present application relates to a crystalline sulfamide compound, and in particular relates to a crystalline (S)&#x2014;N&#x2014;((S)-1-(2-chlorphenyl)-2-((3,3-difluorocyclobutyl)amido)-2oxoethyl)-2-(4-cyanopyridin-2-base)-N-(3-fluorophenyl)-isothiazolidine-3-formamide 1,1-dioxide, and a preparation method therefor, a crystalline composition, a pharmaceutical composition and uses thereof. An X-ray powder diffraction spectrum of a crystalline hydrate of formula II of the present application has diffraction peaks at positions of about 14.40&#xb0;, 20.28&#xb0;, 20.94&#xb0;, 22.02&#xb0;, and 24.46&#xb0;, represented by 2&#x3b8;. The crystalline hydrate of formula II of the present application has good IDH1 inhibitory activity and performs high stability, and therefore has advantages in physical property, safety and metabolic stability, and has high medicine value. 

Crystalline sulfamide compound

The present application relates to a method for preparing a cholic acid compound. Specifically, the method prepares a compound as shown in formula I, including subjecting a compound of formula 2 to an oxidization reaction to obtain a compound of formula 3; attaching a trimethylsilyl group to the compound of formula 3 to obtain a compound of formula 4; reacting the compound of formula 4 with acetaldehyde to obtain a compound of formula 5; subjecting the compound of formula 5 to a catalytic hydrogenation reaction to obtain a compound of formula 6; and converting a cyano group of the compound of formula 6 to a carboxyl group to give the compound of formula I. 

Method for preparing cholic acid compound

Disclosed in the present application are a compound represented by formula (I), or a pharmaceutically acceptable salt, a tautomer thereof, a stereoisomer thereof, or a geometrical isomer thereof, and uses thereof in the preparation of drugs for treating or preventing multiple myeloma. 

Azetidine derivative

The present application relates to a crystal of a compound represented by Formula (I), a salt thereof, and a crystal of the salt thereof, a method for preparing the crystal of the compound represented by Formula (I), the salt thereof, and the crystal of the salt thereof, a crystal comprising the compound represented by Formula (I), a crystal composition comprising the crystal of the salt thereof, a pharmaceutical composition thereof, and medical uses thereof. 

Crystal of DPP-IV long-acting inhibitor and salt

Provided are a preparation method for a chiral pyrrolopyrimidine compound and a related intermediate. In the method, a compound of formula A and a compound of formula 6 or a salt thereof are reacted to obtain a compound of formula 7 or a compound of formula 14, and a compound of formula I is prepared from the compound of formula 7 or the compound of formula 14. Also provided are the intermediate used, a preparation method for the intermediate and a use of the intermediate in the preparation of the compound of formula I. The preparation method has characteristics such as brief steps, a high stereoselectivity, a high utilization ratio of atoms, mild reaction conditions and a convenient post-treatment. The method avoids using an expensive asymmetric reaction catalyst, and is suitable for industrial production. 

Preparation method for chiral pyrrolopyrimidine compound

The present application relates to the field of pharmaceutical chemistry. The application specifically relates to a crystal form A and crystal form B of a pyrrolopyrimidine (formula I) for preparing a JAK inhibitor. The application further relates to a method for preparing the crystal form A and crystal form B, a crystalline composition comprising the crystal form A or crystal form B, a pharmaceutical composition comprising the crystal form A, crystal form B, or crystalline composition, and a pharmaceutical application of the pharmaceutical composition, the crystal form A, and the crystal form B. The crystal form A and crystal form B of the application has the advantages of high purity, high crystallinity, and good stability. 

Pyrrolopyrimidine crystal for preparing JAK inhibitor

The present application falls within the field of drug synthesis, and in particular, the present application relates to a method for preparing ruxolitinib, and a method for preparing the intermediate and relevant intermediates used. The method comprises reacting a compound of formula II with a compound of formula IV or a salt thereof to obtain a compound of formula III, and then subjecting the compound of formula III to an acyl halogenation reaction, an amidation reaction, and a reaction dehydrating an amide to form a cyano group or removing the protecting group to prepare ruxolitinib. The method has the characteristics of brief steps, a high stereoselectivity, a high utilization ratio of atoms, mild reaction conditions and convenient post treatment. The method avoids using expensive asymmetric reaction catalysts, and is suitable for industrial production. 

Synthesis process of ruxolitinib

The present application relates to a method for preparing Ibutinib as shown by the following synthetic route and the intermediate compounds involved therein. 

Process for preparing ibrutinib

The present application relates to a substituted amino six-membered saturated heteroalicycle represented by formula I as a long-acting DPP-IV inhibitor, a method for preparing the same, a pharmaceutical composition comprising the same, and a use of the same in treating and/or preventing diseases and disorders benefitting from DPP-IV inhibition. 

Substituted amino six-membered saturated heteroalicycles as long-acting DPP-IV inhibitors

The present invention relates to a crystalline form of tenofovir dipivoxil fumarate, a crystalline composition and a pharmaceutical composition comprising the crystalline form, and also to a process for preparing the same and the use for prophylaxis or treatment of a disease associated with a viral infection. The crystalline form has an X-ray powder diffraction pattern using Cu-K&#x3b1; radiation, expressed in terms of lattice spacing 'd' comprising peaks at about 18.4714 &#x212b;, 5.0350 &#x212b;, 4.6380 &#x212b;, 4.5347 &#x212b;, 4.3838 &#x212b;, 4.2874 &#x212b; and 3.6304 &#x212b;.

Crystalline forms of tenofovir dipivoxil fumarate

Growing community of inventors

Lianyungang, China

Aiming Zhang